SOUTH SAN FRANCISCO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin,
M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior
vice president and chief financial officer of Cell Genesys, will host a
conference call relating to the company's fourth quarter and year-end
financial results that will be broadcast live over the internet on
Thursday, February 28, 2008, at 2:00 p.m. PT/ 5:00 p.m. ET.
The webcast will be available on the investor relations section of the
company's website, http://www.cellgenesys.com. If you are unable to listen
to the live webcast, the call will be archived on the website for at least
72 hours following the call. To access the replay, go to the Investor
Relations section of the website.
Cell Genesys is focused on the development and commercialization of
novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms -- GVAX(TM) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and
a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell
Genesys continues to hold an equity interest in its former subsidiary,
Ceregene, Inc., which is developing gene therapies for neurodegenerative
disorders. Cell Genesys is headquartered in South San Francisco, CA and has
its principal manufacturing operation in Hayward, CA. For additional
information, please visit the company's website at
http://www.cellgenesys.com.
Contact:
Susan Ferris
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Susan Ferris, Investor Relations of Cell
Genesys, Inc., +1-650-266-3200
|
